Nivolumab and Ipilimumab in Advanced Mismatch Repair–Deficient/Microsatellite Instability–High Noncolorectal Cancers
Matteo S. Carlino(The University of Sydney), Oliver Klein(Olivia Newton-John Cancer Wellness & Research Centre), Craig Underhill(AstraZeneca (United Kingdom)), Rosemary Harrup(University of Tasmania), Robert Zielinski, Henry Marshall(Wellcome Sanger Institute), Ashray Gunjur(Wellcome Sanger Institute), Damien Kee(Peter MacCallum Cancer Centre), Jonathan Cebon(La Trobe University), Ian Collins(St. James's Hospital), John P. Grady(Garvan Institute of Medical Research), S.J. Harris(Bendigo Health), Bo Gao(Sun Yat-sen University), Jane So(Auckland City Hospital), Mandy L. Ballinger(Garvan Institute of Medical Research), Elnaz Tavancheh(Olivia Newton-John Cancer Wellness & Research Centre), Michael P. Brown(Royal Adelaide Hospital), Michael Michael(Ospedale San Donato), David M. Thomas(UNSW Sydney), Megan Lyle(Queensland Health), Jodie Palmer(Olivia Newton-John Cancer Wellness & Research Centre), Howard Chan(Calvary Mater Newcastle Hospital), Wei‐Sen Lam(Fiona Stanley Hospital)
Cited by 5
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k